-
-related datasets is a requirement, as well as being an independent programmer with expertise in R, STATA, SAS, or Python and with advanced knowledge of relevant computational or statistical methods
-
, cultivation of human and/or animal cells, proteomics, immunocytochemistry and flow cytometry. A strong interest in interdisciplinary technology development, and novel and creative thinking. Good interpersonal
-
, Tumor and Cell Biology at Karolinska Institutet (KI) announces an opportunity to join the Bionanomaterial Technology Laboratory and research group of Principal Investigator Assoc. Professor Dr. Georgios A
-
. As part of the Dura-store project we aim to use bio-inspired solutions to address fundamental limitations of the current manifestations of the technology in terms of data stability and dynamic data
-
technology, molecular biology, or AI. Have experience in research with advanced imaging techniques at research infrastructures, as well as an in-depth understanding of working with various imaging techniques
-
interdisciplinary technology development. Suitable candidates should have extensive experience with molecular biology methods such as RNA-Seq, ATAC-Seq, molecular cloning and RNA biology. Research experience with
-
the following documents in English or Swedish: A complete resumé, including date of the thesis defence, title of the thesis, previous academic positions, academic title, current position, academic distinctions
-
applicant has experience in gene editing with Cas9-mediated engineering. It is expected that the candidate should be able to prioritize tasks, meet deadlines, and work independently. Good knowledge in English
-
research with clinical potential. Our lab is in the intersection of biology, chemistry, physics and engineering, aiming to reveal the molecular codes of cellular physiology and diseases. The candidate will
-
a unique automated robotic lab for high-capacity full-length scRNA-seq that can provide state-of-the-art splicing information across complex tissues. Using this scalable scRNA-seq technology, we